Rocket Pharmaceuticals (RCKT) Proxy filing summary

Executive summary

• The 2026 Annual Meeting will be held virtually on May 20, 2026, with voting on key proposals including director elections, auditor ratification, executive compensation, and a stock option exchange program.

• Proxy materials are distributed electronically to reduce costs and environmental impact, with paper copies available upon request.

• The record date for voting eligibility is March 24, 2026, with 109,122,837 shares outstanding.

Voting matters and shareholder proposals

• Shareholders will vote on: election of seven directors, ratification of EisnerAmper LLP as auditor, a non-binding say-on-pay vote, approval of a stock option exchange program, and any other business.

• The Board recommends voting FOR all proposals.

• Shareholder proposals and nominations for the 2027 meeting must be submitted between January 20 and February 19, 2027.

Board of directors and corporate governance

• Seven director nominees are up for election, with two current directors not standing for re-election.

• The Board is majority independent, with regular executive sessions for independent directors.

• The Board has Audit, Compensation, and Nominating and Corporate Governance Committees, all composed of independent directors.

• Board leadership will transition to Dr. Peter Fong as Chairman if elected.